SpringerLink
Log in

Experience in the Use of Valdoxan (agomelatine) in the Treatment of Depression in Patients with Dyscirculatory Encephalopathy

  • Published:
Neuroscience and Behavioral Physiology Aims and scope Submit manuscript

Objective – to study the efficacy and tolerance of agomelatine (Valdoxan) in mild depressive states in patients with chronic cerebral ischemia (CCI). Materials and methods. The study included 33 patients (23 women, 10 men, mean age 54.5 years). Grade I CCI was diagnosed in 12 patients (36.4%) and grade II in 21 (63.6%). All patients had single depressive episodes of mild severity. Diagnoses of affective and cognitive impairments were based on the Hamilton Rating Scale for Depression (HRDS-17), the Hospital Anxiety and Depression Scale (HADS), the Vein Nocturnal Sleep Questionnaire, the Mini Mental State Examination (MMSE), the Mini-Cog test, the Montreal Cognitive Assessment Scale, the physician’s Clinical Global Impression scale for assessment of the severity and dynamics of illness (CGI-S, CGI-I), and the Patients’ Global Impression of Change Scale (PGIC). Investigations were performed at prescription of agent and at 2, 4, and 8 weeks of treatment. All patients received agomelatine (Valdoxan) once daily at a dose of 25 mg. Results and conclusions. Use of agomelatine led to improvements in sleep from week 2, with reductions in anxiety symptoms at six weeks, and reductions in depressive symptomatology at eight weeks of treatment. In addition, treatment with agomelatine produced improvements in cognitive functions in the patients. No patient experienced any treatment side effects. The study results demonstrated high antidepressant activity in the treatment of mild depressive disorders in patients with CCI, with a balanced spectrum of actions in relation to symptoms of anxiety, depression, and dyssomnia, along with positive actions on cognitive functions, allowing the use of agomelatine in the treatment of patients with CCI to be recommended.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Subscribe and save

Springer+ Basic
EUR 32.99 /Month
  • Get 10 units per month
  • Download Article/Chapter or Ebook
  • 1 Unit = 1 Article or 1 Chapter
  • Cancel anytime
Subscribe now

Buy Now

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. A. N. Boiko, T. V. Sidorenko, and A. A. Kabanov, “Chronic cerebral ischemia (dyscirculatory encephalopathy),” Consilium Medicum, 6, No. 8, 598–601 (2004).

    Google Scholar 

  2. S. G. Bugrova and A. E. Novikov, Moderate Cognitive Impairments in Dyscirculatory Encephalopathy, Ivanovo (2006).

  3. V. V. Zakharov and N. N. Yakhno, Cognitive Impairments in the Elderly and Aged: Methodological Guidelines for Doctors, Moscow (2005).

  4. T. G. Voznesenskaya, “Depression in neurological practice and its treatment,” Nevrol. Zh., 11, No. 6, 4–11 (2006).

    Google Scholar 

  5. O. V. Vorob’eva, “Valdoxan in the treatment of depression in neurological practice: results of the ‘Resonance’ Russian multicenter naturalistic study,” Zh. Nevrol. Psikhiat., 112, No. 9, 47–51 (2012).

  6. O. V. Vorob’eva, “Valdoxan in the treatment of depression in neurological practice: results of the Russian ‘Resonance’ multicenter naturalistic study,” Neurosci. Behav. Physiol., 43, No. 9, 1126–1131 (2013), doi: https://doi.org/10.1007/s11055-013-9860-7.

    Article  Google Scholar 

  7. N. V. Pizova, “Valdoxan (agomelatine) in the treatment of depression in cerebrovascular diseases (results of the Russian ‘Resonance’ multicenter naturalistic study,” Zh. Nevrol. Psikhiat., 112, No. 12, 41–45 (2012).

  8. N. V. Pizova, “Valdoxan (agomelatine) in the treatment of depression in cerebrovascular diseases (results of the Russian ‘Resonance’ multicenter naturalistic study),” Neurosci. Behav. Physiol., 44, No. 3, 315–319 (2014), doi: https://doi.org/10.1007/s11055-014-9911-8.

    Article  CAS  Google Scholar 

  9. S. I. Gavrilova, I. V. Kolykhalov, E. V. Ponomareva, and N. D. Selezneva, “Experience in the clinical use of agomelatine for the treatment of depression in elderly patients in out-patient practice,” Zh. Nevrol. Psikhiat., 114, No. 9, 43–48 (2014).

    CAS  Google Scholar 

  10. S. P. Markin, “Current approaches to the treatment of chronic cerebral ischemia,” Rus. Med. Zh., 6, 1–7 (2010).

    Google Scholar 

  11. T. Seki, S. Awata, Y. Koizumi, et al., “Association between depressive symptoms and cerebrovascular lesions on MRI in community-dwelling elderly individuals,” Nippon Ronen Igakkai Zasshi. Jap. J. Geriatr., 43, No. 1, 102–107 (2006), doi: https://doi.org/10.3143/geriatrics.43.102.

    Article  Google Scholar 

  12. V. V. Zakharov, Neuropsychological Impairments: Diagnostic Tests, MEDpress-Inform, Moscow (2013), 2nd ed.

  13. S. V. Ivanov, “Valdoxan (agomelatine) in the treatment of moderate and severe forms of depression at the nonpsychotic level in out-patient and hospital practice (results of the Russian ‘Chronos’ multicenter study,” Psikhiatr. Psikhofarmakoter., 6, 14–17 (2009).

  14. N. N. Yakhno and T. G. Voznesenskaya, “Efficacy and tolerance of agomelatine (Valdoxan) in the treatment of mild and moderate depressive disorders in neurological practice (results of the Russian ‘Kamerton’ multicenter study,” Lekarst. Prep. Nevrol., No. 1, 43–49 (2012).

  15. R. H. McAllister-Williams, D. S. Baldwin, P. M. Haddad, and S. Bazire, “The use of antidepressants in clinical practice: focus on agomelatine,” J. Hum. Psychopharmacol., 25, No. 2, 95–102 (2010), doi: https://doi.org/10.1002/hup.1094.

    Article  CAS  Google Scholar 

  16. O. Yu. Rebrova, Statistical Analysis of Medical Data. Use of the Statistica Program Bundle, Media Sfera, Moscow (2002).

    Google Scholar 

  17. N. N. Petrova, L. A. Leonidova, and E. R. Barantsevich, “Psychological disorders in neurology patients,” Zh. Nevrol. Psikhiat., 106, No. 7, 20–23 (2006).

    CAS  Google Scholar 

  18. E. G. Antonen, M. M. Burkin, M. M. Kruchek, and I. V. Khyanikyainen, “Psychopathological disorders in people with the preclinical stage of cerebral circulatory insufficiency,” Psikh. Rasstr. Obshch. Med., No. 2, 10–13 (2009).

  19. D. R. Dolnak, “Treating patients for comorbid depression, anxiety disorders and somatic illnesses,” J. Am. Osteopath. Assoc., 106, No. 2, 1–8 (2006).

    Google Scholar 

  20. I. B. Hickie and N. L. Rogers, “Novel melatonin-based therapies: potential advances in the treatment of major depression,” Lancet, 378, No. 9791, 621–631 (2011), doi: https://doi.org/10.1016/s0140-6736(11)60095-0.

    Article  CAS  PubMed  Google Scholar 

  21. M. N. Levitan, M. Papelbaum, and A. E. Nardi, “A review of preliminary observations on agomelatine in the treatment of anxiety disorders.” Exp. Clin. Psychopharmacol., 20, No. 6, 504–509 (2012), doi: https://doi.org/10.1037/a0030263.

    Article  CAS  PubMed  Google Scholar 

  22. M. J. Millan, M. Brocco, A. Gobert, and A. Dekeyne, “Anxiolytic properties of agomelatine, an antidepressant with melatoninenergic and serotonergic properties: role of 5-HT2C receptor blockade,” Psychopharmacology (Berl.), 177, No. 4, 448–458 (2005), doi: https://doi.org/10.1007/s00213-004-1962-z.

    Article  CAS  Google Scholar 

  23. M. A. Quera-Salva, P. Lemoine, and C. Guilleminault, “Impact of the novel antidepressant agomelatine on disturbed sleep-wake cycles in depressed patients,” Hum. Psychopharmacol. Clin. Exp., 25, No. 3, 222–229 (2010), doi: https://doi.org/10.1002/hup.1112.

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Petrozavodsk State University, Petrozavodsk, Russia

    E. G. Antonen, M. V. Nikitina & M. M. Kruchek

Authors
  1. E. G. Antonen
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. M. V. Nikitina
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. M. M. Kruchek
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to E. G. Antonen.

Additional information

Translated from Zhurnal Nevrologii i Psikhiatrii imeni S. S. Korsakova, Vol. 115, No. 12, Iss. I, pp. 79–85, December, 2015.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Antonen, E.G., Nikitina, M.V. & Kruchek, M.M. Experience in the Use of Valdoxan (agomelatine) in the Treatment of Depression in Patients with Dyscirculatory Encephalopathy. Neurosci Behav Physi 47, 821–827 (2017). https://doi.org/10.1007/s11055-017-0475-2

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11055-017-0475-2

Keywords

Search

Navigation